ST. LOUIS, May 21 /PRNewswire/ -- Kereos, a biotechnology company developing targeted therapeutics and molecular imaging agents for the treatment and detection of cancer and cardiovascular disease, announced today that the company received the 2004 Governor's Technology Award. The award recognizes the company's innovative products to combat these two diseases.
"Kereos is honored to be recognized for our novel approach to finding and treating cardiovascular disease and cancer, the leading killers of Americans," said Robert "Al" Beardsley, Ph.D., CEO of Kereos. "The products we are developing enable physicians to find very early-stage malignant tumors, to detect and assess the unstable plaque underlying most heart attacks and to directly and effectively treat both. Because we believe these products may help increase life expectancy and reduce the impact of these diseases on patients, we are focused on taking the first of them into clinical trials next year."
The Governor's Technology Award is presented every year to a Missouri company that has developed a new technology, manufacturing process or business practice. The award is being presented during a ceremony today, May 21st, at the annual Governor's Development Conference, taking place at The Lodge of Four Seasons at the Lake of the Ozarks. This joint event with the Department of Economic Development and the Missouri Economic Development Council focuses on innovation, Missouri's cutting-edge technology companies, and the role they are playing in Missouri's economic development.
Cancer and cardiovascular disease kill nearly 2 million persons each year in the U.S. Kereos' novel approach to finding and treating these diseases offers solutions to some of the most urgent unmet needs in each: earlier detection and treatment of cancer, and detection and treatment of unstable plaque. The company's targeted therapeutics seek out biomarkers within blood vessels and carry powerful payloads of proven chemotherapeutics or other drugs directly to the disease site. Their specificity and potency make these therapeutics potentially more effective and less toxic in treating disease. Similarly, the specificity of Kereos' targeted imaging agents enable much earlier detection of disease, as well as the diagnosis of some disease conditions that could not previously be identified using other approaches.
Kereos develops products designed to provide more effective treatment and detection of cancer and cardiovascular disease, the first of which is expected to enter clinical trials in 2005. In addition to advancing its pipeline of therapeutic and imaging candidates independently, Kereos is committed to partnering with leading pharmaceutical and imaging companies. To date, it has formed collaborations with Bristol-Myers Squibb Medical Imaging for the development and commercialization of cardiovascular disease magnetic resonance imaging (MRI) agents and with Philips Medical Systems for the development of molecular imaging systems. For more information, visit Kereos' website at http://www.kereos.com/ .